Inflammatory Bowel Disease in Children.

Children Diagnosis Guideline Inflammatory bowel disease Management

Journal

Indian journal of pediatrics

ISSN: 0973-7693

Titre abrégé: Indian J Pediatr

Pays: India

ID NLM: 0417442

Informations de publication

Date de publication:
20 Jun 2023

Historique:

received: 07 11 2022

accepted: 19 04 2023

medline: 20 6 2023

pubmed: 20 6 2023

entrez: 20 6 2023

Statut: aheadofprint

Résumé

Inflammatory bowel disease is an important cause of chronic diarrhea in children, with a rising incidence, globally. The two main subtypes include Crohn's disease and ulcerative colitis. The clinical features are variable, and diagnosis requires initial first-line investigations followed by the involvement of specialist input for targeted imaging and endoscopy with biopsy, to confirm the diagnosis. Despite detailed investigation, inflammatory bowel disease may be clinically indistinguishable from chronic infections such as intestinal tuberculosis, and anti-tuberculosis treatment may be considered prior to further management considerations. The medical management of inflammatory bowel disease depends on subtype classification and severity, and may involve a step-wise approach to immunosuppressive therapies. In children, the consequences of poorly controlled disease are wide ranging, from psychosocial impacts and school non-attendance, to growth impairment and pubertal delay with subsequent impacts on bone health. In addition, an increased need for hospitalization and surgical intervention, and ultimately risk of cancer long-term. A multi-disciplinary team with expertise in inflammatory bowel disease is recommended to mitigate these risks and help to achieve the goal of sustained remission with endoscopic healing. This review focuses on updates on best clinical practice on the diagnosis and management of inflammatory bowel disease in children.

Identifiants

DOI: 10.1007/s12098-023-04671-0 PMID: 37338669

pubmed: 37338669

doi: 10.1007/s12098-023-04671-0

pii: 10.1007/s12098-023-04671-0

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91–9.

doi: 10.3748/wjg.v20.i1.91 pubmed: 24415861 pmcid: 3886036

Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990–1007.e3.

Huang JG, Aw MM. Pediatric inflammatory bowel disease in Asia: Epidemiology and natural history. Pediatr Neonatol. 2020;61:263–71.

doi: 10.1016/j.pedneo.2019.12.008 pubmed: 32005607

Roberts SE, Thorne K, Thapar N, et al. A systematic review and meta-analysis of paediatric inflammatory bowel disease incidence and prevalence across Europe. J Crohns Colitis. 2020;14:1119–48.

doi: 10.1093/ecco-jcc/jjaa037 pubmed: 32115645

Pipaliya N, Ingle M, Rathi C, Poddar P, Pandav N, Sawant P. Spectrum of chronic small bowel diarrhea with malabsorption in Indian subcontinent: Is the trend really changing? Intest Res. 2016;14:75–82.

doi: 10.5217/ir.2016.14.1.75 pubmed: 26884738 pmcid: 4754526

Rajbhandari R, Blakemore S, Gupta N, et al. Crohn’s disease in low and lower-middle income countries: A scoping review. World J Gastroenterol. 2020;26:6891–908.

doi: 10.3748/wjg.v26.i43.6891 pubmed: 33268969 pmcid: 7684456

Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.

doi: 10.1097/MPG.0000000000000239 pubmed: 24231644

Harbord M, Annese V, Vavricka SR, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239–54.

doi: 10.1093/ecco-jcc/jjv213 pubmed: 26614685

Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637–45.

doi: 10.1038/ajg.2013.131 pubmed: 23670113

Zhu Q, Li F, Wang J, Shen L, Sheng X. Fecal calprotectin in healthy children aged 1–4 years. PLoS ONE. 2016;11:e0150725.

doi: 10.1371/journal.pone.0150725 pubmed: 26950440 pmcid: 4780696

Pulimood AB, Peter S, Ramakrishna B, et al. Segmental colonoscopic biopsies in the differentiation of ileocolic tuberculosis from Crohn’s disease. J Gastroenterol Hepatol. 2005;20:688–96.

doi: 10.1111/j.1440-1746.2005.03814.x pubmed: 15853980

Lee YJ, Yang SK, Byeon JS, et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn’s disease. Endoscopy. 2006;38:592–7.

doi: 10.1055/s-2006-924996 pubmed: 16673312

Calabrese E, Maaser C, Zorzi F, et al. Bowel ultrasonography in the management of crohn's disease. a review with recommendations of an international panel of experts. Inflamm Bowel Dis. 2016;22:1168–83.

Allocca M, Fiorino G, Bonovas S, et al. Accuracy of humanitas ultrasound criteria in assessing disease activity and severity in ulcerative colitis: A prospective study. J Crohns Colitis. 2018;12:1385–91.

doi: 10.1093/ecco-jcc/jjy107 pubmed: 30085066 pmcid: 6260119

van Wassenaer EA, de Voogd FAE, van Rijn RR, et al. Diagnostic accuracy of transabdominal ultrasound in detecting intestinal inflammation in paediatric ibd patients-A systematic review. J Crohns Colitis. 2019;13:1501–9.

doi: 10.1093/ecco-jcc/jjz085 pubmed: 31329839 pmcid: 7142400

Thurgate LE, Lemberg DA, Day AS, Leach ST. An overview of inflammatory bowel disease unclassified in children. Inflamm Intest Dis. 2019;4:97–103.

doi: 10.1159/000501519 pubmed: 31559261 pmcid: 6751433

Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35–40.

doi: 10.1016/j.jpeds.2004.08.043 pubmed: 15644819

Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017;389:1710–8.

doi: 10.1016/S0140-6736(17)30317-3 pubmed: 28259484 pmcid: 5719489

van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric crohn’s disease: An ECCO-ESPGHAN Guideline update. J Crohns Colitis. 2020. https://doi.org/10.1093/ecco-jcc/jjaa161 .

doi: 10.1093/ecco-jcc/jjaa161 pubmed: 33026087

Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570–83.

doi: 10.1053/j.gastro.2020.12.031 pubmed: 33359090

Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, Part 1: Ambulatory care-an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–91.

doi: 10.1097/MPG.0000000000002035 pubmed: 30044357

Cezard JP, Munck A, Mouterde O, et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn’s disease: A multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol Clin Biol. 2009;33:31–40.

doi: 10.1016/j.gcb.2008.07.007 pubmed: 19118966

Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2016;9:CD003715.

Turner D, Yerushalmi B, Kori M, et al. Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: A randomised controlled trial. J Crohns Colitis. 2017;11:527–33.

pubmed: 28453754

Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8:CD000543.

Swaminath A, Feathers A, Ananthakrishnan AN, Falzon L, Li FS. Systematic review with meta-analysis: Enteral nutrition therapy for the induction of remission in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2017;46:645–56.

doi: 10.1111/apt.14253 pubmed: 28815649 pmcid: 5798240

Pigneur B, Lepage P, Mondot S, et al. Mucosal healing and bacterial composition in response to enteral nutrition vs steroid-based induction therapy-a randomised prospective clinical trial in children with crohn’s disease. J Crohns Colitis. 2019;13:846–55.

doi: 10.1093/ecco-jcc/jjy207 pubmed: 30541015

Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: A randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744–53.

doi: 10.1016/j.cgh.2006.03.010 pubmed: 16682258

Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30:501–7.

doi: 10.1111/j.1365-2036.2009.04067.x pubmed: 19549288

Rubio A, Pigneur B, Garnier-Lengline H, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011;33:1332–9.

Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157:440–50.e8.

Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895–902.

doi: 10.1053/gast.2000.18144 pubmed: 11040176

Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138–43.

doi: 10.1002/ibd.21612 pubmed: 21910176

Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58 e4; quiz e48–50.

Carbonnel F, Colombel JF, Filippi J, et al; European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150:380–8 e4.

Herfarth H, Barnes EL, Valentine JF, et al; Clinical Research Alliance of the Crohn’s and Colitis Foundation. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018;155:1098–108 e9.

Turner D, Doveh E, Cohen A, et al. Efficacy of oral methotrexate in paediatric Crohn’s disease: A multicentre propensity score study. Gut. 2015;64:1898–904.

doi: 10.1136/gutjnl-2014-307964 pubmed: 25416066

Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-tnf in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20102529 .

doi: 10.3390/ijms20102529 pubmed: 31126015 pmcid: 6566820

Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN clinical report: Surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-alpha inhibitors. J Pediatr Gastroenterol Nutr. 2016;63:130–55.

doi: 10.1097/MPG.0000000000001188 pubmed: 27027903

Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655–68.e3.

El-Matary W, Walters TD, Huynh HQ, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal crohn's disease in children. inflamm bowel dis. 2019;25:150–5.

Thavamani A, Umapathi KK, Khatana J, Gulati R. Burden of psychiatric disorders among pediatric and young adults with inflammatory bowel disease: A population-based analysis. Pediatr Gastroenterol Hepatol Nutr. 2019;22:527–35.

doi: 10.5223/pghn.2019.22.6.527 pubmed: 31777718 pmcid: 6856511

Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53:11–25. https://doi.org/10.1097/MPG.0b013e31821988a3 .

doi: 10.1097/MPG.0b013e31821988a3 pubmed: 21694532 pmcid: 3122140

Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–53.

doi: 10.1016/j.dld.2008.01.017 pubmed: 18358796